Toujeo approved in the EU for the treatment of diabetes in adults

The European Commission has granted marketing authorisation in Europe for Sanofi’s Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a next-generation basal insulin for the treatment of type 1 and type 2 diabetes mellitus in adults.

“The EU marketing authorisation for Toujeo represents a significant milestone for Sanofi, expanding our integrated portfolio of solutions for people with diabetes in Europe,” commented Pierre Chancel, Senior Vice-President, Global Diabetes, Sanofi. “Toujeo gives people with diabetes and their physicians a new option to manage their condition, and also reinforces our commitment to continue improving the quality of diabetes care.”

Decision to grant marketing authorisation for Toujeo based on results from the EDITION programme

The European Commission’s decision to grant marketing authorisation in Europe for Toujeo is based on results from the EDITION clinical trial programme, a series of worldwide Phase III studies evaluating the efficacy and safety of Toujeo compared with Lantus® (insulin glargine [rDNA origin] injection, 100 U/mL) in more than 3,500 adults with type 1 or type 2 diabetes who were uncontrolled on their current therapy.

Blood sugar control with Toujeo was comparable to Lantus, with a favourable safety profile. The incidence of confirmed hypoglycaemia was lower with Toujeo as compared to Lantus, both at any time of the day and at night, in people with type 2 diabetes. Toujeo also demonstrated more stable and more predictable glycaemic control and low within-individual blood sugar variability that lasted beyond 24 hours compared with Lantus in people with type 1 diabetes.

“Many people living with diabetes and requiring insulin are still not achieving adequate blood sugar control,” said Professor Robert Ritzel, Head of the Clinic of Endocrinology, Diabetology and Addiction Medicine, Klinikum Schwabing, Städtisches Klinikum München GmbH, Munich, Germany. “By providing glycaemic stability and less variability, as well as reducing hypoglycaemic events in people with type 2 diabetes, Toujeo provides a new way to address these unmet needs.”

Marketing authorisation in Europe for Toujeo is applicable to the 28 member states of the European Union, as well as Iceland, Lichtenstein and Norway, and follows an earlier positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Toujeo has been approved by the U.S. Food and Drug Administration (FDA) and is under review by other regulatory authorities around the world.